[Genetic polymorphism of cytochrome P450 2E1 and the risk of nasopharyngeal carcinoma].

Autor:	Ben Chaaben A; Institut Salah Azaiz, laboratoire de biologie Clinique, Tunis, Tunisie. Electronic address: arijnour_06@yahoo.fr., Abaza H; Institut Salah Azaiz, laboratoire de biologie Clinique, Tunis, Tunisie., Douik H; Institut Salah Azaiz, laboratoire de biologie Clinique, Tunis, Tunisie., Chaouch L; Institut Pasteur de Tunis, laboratoire d'hématologie moléculaire et cellulaire, Tunis, Tunisie., Ayari F; Institut Salah Azaiz, laboratoire de biologie Clinique, Tunis, Tunisie., Ouni N; Institut Salah Azaiz, laboratoire de biologie Clinique, Tunis, Tunisie., Mamoghli T; Institut Salah Azaiz, laboratoire de biologie Clinique, Tunis, Tunisie., Ben Guezella D; Institut Salah Azaiz, laboratoire de biologie Clinique, Tunis, Tunisie., Mejri R; Institut Salah Azaiz, laboratoire de biologie Clinique, Tunis, Tunisie., Harzallah L; Institut Salah Azaiz, laboratoire de biologie Clinique, Tunis, Tunisie., Guemira F; Institut Salah Azaiz, laboratoire de biologie Clinique, Tunis, Tunisie.
Jazyk:	francouzština
Zdroj:	Bulletin du cancer [Bull Cancer] 2015 Dec; Vol. 102 (12), pp. 967-72. Date of Electronic Publication: 2015 Nov 12.
DOI:	10.1016/j.bulcan.2015.09.013
Abstrakt:	Cytochrome P450 2E1 (CYP2E1) is a detoxifying enzyme that belongs to the phase I metabolism of xenobiotics. This enzyme is encoded by a highly polymorphic gene whose common polymorphism corresponds to the substitution of cytosine (C) and thymine (T) at position -1019 (rs2031920). This polymorphism has been identified in several cancers including nasopharyngeal cancer (NPC). The study involved 124 patients with nasopharyngeal carcinoma, compared with 166 healthy controls. The presence or absence of the polymorphism is determined by PCR-RFLP. The frequency comparison between the two groups is determined by the χ(2) test. The analysis of our results showed a significant difference between the two groups regarding the mutant genotype (C2/C2) (5% vs. 0.5%, P=0.04) and has a risk factor for NPC in Tunisia (OR=8.39; CI 95% [0.99-388.1]). Also, the C2 allele was significantly associated with the group of patients than the control group (6% vs. 2%, P=0.016) and increased three times the risk of NPC in Tunisia (OR=2.99, CI 95% [1.12-8.79]). Our results confirm the results reported in other populations and emphasize the importance of the involvement of this gene in the development of detoxification of the NPC, which seems more and more strongly associated with environmental factors. (Copyright © 2015 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu